Maintenance oral viscous budesonide reduces dilation recurrence after esophageal atresia repair: a prospective clinical study - Top-Institutions - MDSpire

Maintenance oral viscous budesonide reduces dilation recurrence after esophageal atresia repair: a prospective clinical study

  • By

  • Cosimo Ruggiero

  • Giusy Russo

  • Denis Cozzi

  • Danila Volpe

  • Silvia Ceccanti

  • Paola Papoff

  • Miriam D’Orsi

  • Tonia Raso

  • Giulia Mancuso

  • Salvatore Oliva

  • May 14, 2026

  • 0 min

Share

Top Institutions in Gastroenterology

Brief introduction explaining scope and methodology.

  • #1

    Sapienza – University of Rome
    Sapienza – University of Rome

    Rome, Italy

    Key Differentiators

    • Pediatric Surgery
    • Pediatric Gastroenterology

  • #2

    CHU Sainte-Justine (Université de Montréal)
    CHU Sainte-Justine (Université de Montréal)

    Montréal, Québec

    Key Differentiators

    • Pediatric Surgery
    • Esophageal Atresia

  • #3

    IRCCS Ospedale San Raffaele
    IRCCS Ospedale San Raffaele

    Milan, Italy

    Key Differentiators

    • Pediatric Surgery

  • #4

    The Ann & Robert H. Lurie Children’s Hospital of Chicago
    The Ann & Robert H. Lurie Children’s Hospital of Chicago

    Chicago, Illinois

    Key Differentiators

    • Pediatric Surgery

  • #5

    Medical University of Vienna
    Medical University of Vienna

    Vienna, Austria

    Key Differentiators

    • Pediatric Surgery

Original Source(s)

Maintenance oral viscous budesonide reduces dilation recurrence after esophageal atresia repair: a prospective clinical study

  • by Cosimo Ruggiero, Giusy Russo, Denis Cozzi, Danila Volpe, Silvia Ceccanti, Paola Papoff, Miriam D’Orsi, Tonia Raso, Giulia Mancuso, Salvatore Oliva

  • May 14, 2026

Related Content

Case Report: Massive rectal bleeding from stercoral ulcers in a pediatric patient

Reactive lymphoid hyperplasia of the appendix in children: a descriptive analysis of accompanying neural and stromal features

Tumor-localized CD40 agonism with MP0317, a FAP x CD40 DARPin, reprograms the tumor microenvironment in patients with advanced solid tumors: an open-label, nonrandomized, dose-escalation phase 1 study